Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
J Pharm Biomed Anal. 2021 Sep 10;204:114274. doi: 10.1016/j.jpba.2021.114274. Epub 2021 Jul 21.
JQ1, is a cell-permeable small-molecule inhibitor of bromodomain and extra-terminal protein (BET) function with reportedly good CNS penetration, however, unbound and pharmacologically active CNS JQ1 exposures have not been characterized. Additionally, no quantitative bioanalytical methods for JQ1 have been described in the literature to support the CNS penetration studies. In the present article, we discuss the development and validation of a sensitive and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantitative methods to determine JQ1 in mouse plasma and brain microdialysate. JQ1 and the internal standard, dabrafenib (ISTD), were extracted from plasma and microdialysate samples using a simple solid phase extraction protocol performed on an Oasis HLB μElution plate. Chromatographic separation of JQ1 and ISTD was achieved on a reversed phase C analytical column with gradient elution profile of mobile phases (MP A: water containing 0.1 % formic acid and MP B: acetonitrile containing 0.1 % formic acid) at a flow rate of 0.6 mL/min. The mass spectrometric detection was performed in the positive MRM ion mode by monitoring the transitions 457.40 > 341.30 (JQ1) and 520.40 > 307.20 (ISTD). The calibration curves demonstrated good linearities over the concentration range of 5-1000 ng/mL for the mouse plasma method (r ≥ 0.99) and 0.5-500 ng/mL for the microdialysate method (r ≥ 0.99). The experimental limit of quantification obtained was 5 and 0.5 ng/mL for the mouse plasma and microdialysate method, respectively, with the coefficient of variation less than 10 % for the analyte peak area. All the other validation parameters, including intra-and inter-day accuracy and precision, matrix effect, selectivity, carryover effect, and stability, were within the USFDA bioanalytical guidelines acceptance limits. The LC-MS/MS method was successfully applied to a mouse pharmacokinetic and cerebral microdialysis study to characterize the unbound JQ1 exposure in brain extracellular fluid and plasma.
JQ1 是一种细胞通透性的小分子抑制剂,可抑制溴结构域和末端外蛋白(BET)的功能,据称其具有良好的中枢神经系统穿透性,然而,未结合的和具有药理活性的中枢神经系统 JQ1 暴露情况尚未得到描述。此外,文献中尚未描述用于支持中枢神经系统穿透研究的 JQ1 的定量生物分析方法。在本文中,我们讨论了开发和验证一种灵敏且可靠的液相色谱-串联质谱(LC-MS/MS)定量方法,以测定小鼠血浆和脑微透析液中的 JQ1。JQ1 和内标 dabrafenib(ISTD)使用 Oasis HLB μElution 板上的简单固相萃取方案从血浆和微透析液样品中提取。JQ1 和 ISTD 的色谱分离在反相 C 分析柱上实现,采用流动相(MP A:含 0.1%甲酸的水和 MP B:含 0.1%甲酸的乙腈)的梯度洗脱程序,流速为 0.6mL/min。质谱检测采用正 MRM 离子模式,通过监测 457.40 > 341.30(JQ1)和 520.40 > 307.20(ISTD)的跃迁进行。小鼠血浆方法的校准曲线在 5-1000ng/mL 浓度范围内表现出良好的线性关系(r≥0.99),微透析液方法的校准曲线在 0.5-500ng/mL 浓度范围内表现出良好的线性关系(r≥0.99)。小鼠血浆和微透析液方法的实验定量下限分别为 5 和 0.5ng/mL,分析物峰面积的变异系数小于 10%。所有其他验证参数,包括日内和日间精密度和准确度、基质效应、选择性、残留效应和稳定性,均符合美国 FDA 生物分析指南的可接受标准。LC-MS/MS 方法成功应用于小鼠药代动力学和脑微透析研究,以描述脑细胞外液和血浆中未结合的 JQ1 暴露情况。